187 related articles for article (PubMed ID: 17558103)
1. Homocysteine in cardiovascular disease: a culprit or an innocent bystander?
Kothekar MA
Indian J Med Sci; 2007 Jun; 61(6):361-71. PubMed ID: 17558103
[TBL] [Abstract][Full Text] [Related]
2. Homocysteine and cardiovascular disease: current evidence and future prospects.
Mangoni AA; Jackson SH
Am J Med; 2002 May; 112(7):556-65. PubMed ID: 12015248
[TBL] [Abstract][Full Text] [Related]
3. Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients.
Suliman ME; Lindholm B; Bárány P; Qureshi AR; Stenvinkel P
Semin Dial; 2007; 20(6):523-9. PubMed ID: 17991198
[TBL] [Abstract][Full Text] [Related]
4. Updating the relationship between hyperhomocysteinemia lowering therapy and cardiovascular events.
Cheng X
Cardiovasc Ther; 2013 Aug; 31(4):e19-26. PubMed ID: 23082962
[TBL] [Abstract][Full Text] [Related]
5. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
[TBL] [Abstract][Full Text] [Related]
6. [Hyperhomocysteinemia in pediatric age and nutritional aspects of folates: an early cardiovascular risk factor].
Caramia G; Belardinelli R
Monaldi Arch Chest Dis; 2006 Dec; 66(4):275-85. PubMed ID: 17312847
[TBL] [Abstract][Full Text] [Related]
7. DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations.
Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M;
Clin Chem Lab Med; 2003 Nov; 41(11):1392-403. PubMed ID: 14656016
[TBL] [Abstract][Full Text] [Related]
8. Homocysteine: an emergent cardiovascular risk factor?
Medina MA; Amores-Sánchez MI
Eur J Clin Invest; 2000 Sep; 30(9):754-62. PubMed ID: 10998074
[TBL] [Abstract][Full Text] [Related]
9. Homocysteine and cardiovascular risk.
Scott JM
Am J Clin Nutr; 2000 Aug; 72(2):333-4. PubMed ID: 10919922
[No Abstract] [Full Text] [Related]
10. The controversy over homocysteine and cardiovascular risk.
Ueland PM; Refsum H; Beresford SA; Vollset SE
Am J Clin Nutr; 2000 Aug; 72(2):324-32. PubMed ID: 10919921
[TBL] [Abstract][Full Text] [Related]
11. Homocysteine: is it a clinically important cardiovascular risk factor?
Lentz SR; Haynes WG
Cleve Clin J Med; 2004 Sep; 71(9):729-34. PubMed ID: 15478704
[TBL] [Abstract][Full Text] [Related]
12. Homocysteine and cardiovascular disease.
Kalra DK
Curr Atheroscler Rep; 2004 Mar; 6(2):101-6. PubMed ID: 15023293
[TBL] [Abstract][Full Text] [Related]
13. The factors that affect plasma homocysteine levels, pulse wave velocity and their relationship with cardiovascular disease indicators in peritoneal dialysis patients.
Ertek S; Torun AN; Ates K
Int Urol Nephrol; 2010 Mar; 42(1):211-8. PubMed ID: 19653113
[TBL] [Abstract][Full Text] [Related]
14. Homocysteine and cardiovascular disease: a review of the evidence.
Wierzbicki AS
Diab Vasc Dis Res; 2007 Jun; 4(2):143-50. PubMed ID: 17654449
[TBL] [Abstract][Full Text] [Related]
15. Homocysteine as a risk factor for cardiovascular disease: should we (still) worry about?
Faeh D; Chiolero A; Paccaud F
Swiss Med Wkly; 2006 Dec; 136(47-48):745-56. PubMed ID: 17225194
[TBL] [Abstract][Full Text] [Related]
16. Hyperhomocysteinemia and cardiovascular disease in animal model.
Azad MAK; Huang P; Liu G; Ren W; Teklebrh T; Yan W; Zhou X; Yin Y
Amino Acids; 2018 Jan; 50(1):3-9. PubMed ID: 29018979
[TBL] [Abstract][Full Text] [Related]
17. [Hyperhomocysteinemia and cardiometabolic risk].
Vannucchi H; Melo SS
Arq Bras Endocrinol Metabol; 2009 Jul; 53(5):540-9. PubMed ID: 19768245
[TBL] [Abstract][Full Text] [Related]
18. Homocysteine, cardiovascular inflammation, and myocardial remodeling.
Finch JM; Joseph J
Cardiovasc Hematol Disord Drug Targets; 2010 Dec; 10(4):241-5. PubMed ID: 20932268
[TBL] [Abstract][Full Text] [Related]
19. Interactions of hyperhomocysteinemia and T cell immunity in causation of hypertension.
Veeranki S; Gandhapudi SK; Tyagi SC
Can J Physiol Pharmacol; 2017 Mar; 95(3):239-246. PubMed ID: 27398734
[TBL] [Abstract][Full Text] [Related]
20. [Homocysteine as health risk: who is affected?].
Kinderkrankenschwester; 2009 Aug; 28(8):327. PubMed ID: 19728469
[No Abstract] [Full Text] [Related]
[Next] [New Search]
